1. Home
  2. DMAC vs TWN Comparison

DMAC vs TWN Comparison

Compare DMAC & TWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DMAC
  • TWN
  • Stock Information
  • Founded
  • DMAC 2000
  • TWN 1986
  • Country
  • DMAC United States
  • TWN Hong Kong
  • Employees
  • DMAC N/A
  • TWN N/A
  • Industry
  • DMAC Biotechnology: Pharmaceutical Preparations
  • TWN Trusts Except Educational Religious and Charitable
  • Sector
  • DMAC Health Care
  • TWN Finance
  • Exchange
  • DMAC Nasdaq
  • TWN Nasdaq
  • Market Cap
  • DMAC 267.7M
  • TWN 278.0M
  • IPO Year
  • DMAC N/A
  • TWN N/A
  • Fundamental
  • Price
  • DMAC $6.51
  • TWN $38.32
  • Analyst Decision
  • DMAC Strong Buy
  • TWN
  • Analyst Count
  • DMAC 3
  • TWN 0
  • Target Price
  • DMAC $7.00
  • TWN N/A
  • AVG Volume (30 Days)
  • DMAC 81.8K
  • TWN 20.1K
  • Earning Date
  • DMAC 03-18-2025
  • TWN 01-01-0001
  • Dividend Yield
  • DMAC N/A
  • TWN 1.10%
  • EPS Growth
  • DMAC N/A
  • TWN N/A
  • EPS
  • DMAC N/A
  • TWN N/A
  • Revenue
  • DMAC N/A
  • TWN N/A
  • Revenue This Year
  • DMAC N/A
  • TWN N/A
  • Revenue Next Year
  • DMAC N/A
  • TWN N/A
  • P/E Ratio
  • DMAC N/A
  • TWN N/A
  • Revenue Growth
  • DMAC N/A
  • TWN N/A
  • 52 Week Low
  • DMAC $2.14
  • TWN $25.22
  • 52 Week High
  • DMAC $6.82
  • TWN $41.51
  • Technical
  • Relative Strength Index (RSI)
  • DMAC 62.22
  • TWN 45.98
  • Support Level
  • DMAC $5.75
  • TWN $37.40
  • Resistance Level
  • DMAC $6.82
  • TWN $39.40
  • Average True Range (ATR)
  • DMAC 0.30
  • TWN 1.03
  • MACD
  • DMAC 0.02
  • TWN 0.25
  • Stochastic Oscillator
  • DMAC 74.48
  • TWN 61.22

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.

About TWN Taiwan Fund Inc. (The)

Taiwan Fund Inc is a diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investment predominantly in equity securities listed in Taiwan stock exchange and the Republic of China. In selecting the companies for investments fund's portfolio managers will consider overall growth prospects, competitive position in the respective industry technology, research, and development, productivity, profit margins, return on investment, capital resources, government regulation, management and other factors.

Share on Social Networks: